We are seeking candidates for a NGS Bioinformatics programmer position with our client Mayo Clinic in Rochester, MN. Candidate will work in a team who are Developing tools necessary to implement a wide range of Next Generation Sequencing (NGS) tests from small gene panels to Whole Genome Sequencing, to the Epigenome and Microbiome tests. This is a one year position and could extend or hired as full-time employee at the end of the assignment. Required Qualifications are Next Generation Sequencing knowledge of software variant alignment and callers as well as methods and best practices. Working knowledge of Unix/Linux and experience with developing software pipelines that execute genetics tests from instrument data handling through Patient results analysis. Skilled in the validation and testing of NGS pipelines, generating Golden Data sets and working to verify fully functional systems. Background in creating and managing production IT solutions for Genetics and/or Bioinformatics a plus. Software development skills using Python, Bash scripting is required. Candidates will work in an Agile environment. Version Control, Software testing experience is required. If you are interested, please get in touch [email protected] or 507-289-9956. Thank you.
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Today, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM